Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Gustave Roussy, Cancer Campus, Grand Paris

🇫🇷France

Country: 🇫🇷France

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

Long Term Brain Toxicity of Chemotherapy in Patients Treated for a Bone TumorDuring Childhood or Adolescence

Not Applicable

Recruiting

Conditions: Adults Treated During Childhood or Adolescence for a Malignant Bone Tumor (Osteosarcoma and Ewing Sarcoma)

First Posted Date: 2021-10-07

Last Posted Date: 2021-10-07

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 530

Registration Number: NCT05071001

Locations: 🇫🇷
Gustave Roussy, Villejuif, France

Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer

Phase 2

Active, not recruiting

Conditions: Metastatic Breast Cancer
Advanced Breast Cancer

Interventions: Drug: U3-1402

First Posted Date: 2021-07-16

Last Posted Date: 2025-02-10

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 99

Registration Number: NCT04965766

Locations: 🇫🇷
Centre Georges François Leclerc, Dijon, France
🇫🇷
CHU de Limoges, Limoges, France
🇫🇷
Centre Léon Bérard, Lyon, France

and more 8 locations

Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer

Phase 2

Active, not recruiting

Conditions: Metastatic Lung Cancer
Advanced Non Small Cell Lung Cancer
Unresectable Non-small Lung Cancer

Interventions: Drug: DS-1062a

First Posted Date: 2021-06-25

Last Posted Date: 2025-05-08

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 100

Registration Number: NCT04940325

Locations: 🇫🇷
Institut Bergonié, Bordeaux, France
🇫🇷
Institut de Cancérologie, CHRU Morvan de Brest, Brest, France
🇫🇷
Centre François Baclesse, Caen, France

and more 6 locations

Gustave Roussy Cancer Profiling

Not Applicable

Recruiting

Conditions: Solid Tumor, Unspecified, Adult

First Posted Date: 2021-06-21

Last Posted Date: 2025-06-26

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 20000

Registration Number: NCT04932525

Locations: 🇫🇷
Hôpital Marie-Lannelongue, Le Plessis-Robinson, France
🇫🇷
Hôpital Saint-Joseph, Paris, France
🇫🇷
Hôpital Foch, Suresnes, France

and more 1 locations

Study Evaluating Near-infrared Imaging Coupled With Indocyanine Green for Intraoperative Control of Resection Margins in ENT Surgery

Phase 2

Recruiting

Conditions: Head and Neck Cancer

Interventions: Drug: indocyanine green

First Posted Date: 2021-04-13

Last Posted Date: 2025-04-13

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 65

Registration Number: NCT04842162

Locations: 🇧🇪
Institut Jules Bordet, Anderlecht, Belgium
🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France

Pasireotide to Reduce Clinically Relevant Digestive Leakage After Complete Cytoreductive Surgery (CRS) Plus Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) for Peritoneal Carcinomatosis

Phase 2

Terminated

Conditions: Peritoneal Carcinomatosis

Interventions: Other: Saline water
Drug: Pasireotide 0.9 MG/ML

First Posted Date: 2021-04-01

Last Posted Date: 2024-02-08

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 6

Registration Number: NCT04826432

Locations: 🇫🇷
Gustave Roussy, Villejuif, France

Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to PARP Inhibitors in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With PARP Inhibitors Since at Least 6 Months

Phase 1

Terminated

Conditions: Ovarian Cancer

Interventions: Drug: AsiDNA
Drug: Niraparib
Drug: Olaparib
Drug: Rucaparib

First Posted Date: 2021-04-01

Last Posted Date: 2024-12-05

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 13

Registration Number: NCT04826198

Locations: 🇫🇷
CHU Jean Minjoz, Besançon, Besancon, France
🇫🇷
Hospices civils de Lyon(CHU Lyon Sud), Pierre-Bénite, Lyon, France
🇫🇷
Institut de Cancérologie de l'Ouest - St Herblain, Saint-Herblain, Nantes, France

and more 3 locations

USE OF 18FDG PET-CT TO PREDICT THE RESPONSE OF MANDIBULAR OSTEORADIONECROSIS TO THE PENTOCLO PROTOCOL WITH DOCUMENTED ANTIBIOTHERAPY

Conditions: Mandibular Osteoradionecrosis

First Posted Date: 2021-04-01

Last Posted Date: 2021-04-01

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 75

Registration Number: NCT04826445

Locations: 🇫🇷
Gustave Roussy, Villejuif, France

Hepatic Intra-Arterial Administration of Ipilimumab in Combination With Intra-venous Nivolumab for Advanced Hepatocellular Carcinoma

Phase 1

Recruiting

Conditions: Hepatocellular Carcinoma

Interventions: Drug: Nivolumab
Drug: Ipilimumab

First Posted Date: 2021-03-30

Last Posted Date: 2024-07-26

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 27

Registration Number: NCT04823403

Locations: 🇫🇷
Gustave Roussy, Villejuif, France

Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab

Phase 2

Suspended

Conditions: Biliary Tract Cancer
Gastro-oesophageal Adenocarcinoma
Head and Neck Cancer
Urothelial Bladder Cancer
Clear Cell Renal Cell Carcinoma
Gastric Adenocarcinoma
Pancreatic Ductal Adenocarcinoma
Platinum-sensitive Urothelial Bladder Cancer

Interventions: Drug: Dostarlimab
Drug: Niraparib

First Posted Date: 2021-03-03

Last Posted Date: 2024-03-26

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 51

Registration Number: NCT04779151

Locations: 🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy